234 related articles for article (PubMed ID: 32499072)
1. Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
Chambers LM; Pendlebury A; Rose PG; Yao M; DeBernardo R
Gynecol Oncol; 2020 Aug; 158(2):309-315. PubMed ID: 32499072
[TBL] [Abstract][Full Text] [Related]
2. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study.
Blake EA; Bradley CA; Mostofizadeh S; Muggia FM; Garcia AA; Roman LD; Matsuo K
Arch Gynecol Obstet; 2019 Jun; 299(6):1641-1649. PubMed ID: 30824986
[TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Lawrie TA; Bryant A; Cameron A; Gray E; Morrison J
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006910. PubMed ID: 23835762
[TBL] [Abstract][Full Text] [Related]
5. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
6. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.
Mayer C; Brucker J; Schuetz F; Domschke C; Bechstein S; Heil J; Golatta M; Wallwiener M; Sohn C; Schneeweiss A; Rom J
Arch Gynecol Obstet; 2016 Jul; 294(1):123-9. PubMed ID: 26498757
[TBL] [Abstract][Full Text] [Related]
8. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
9. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract][Full Text] [Related]
10. Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial.
Wang T; Tang J; Yang H; Yin R; Zhang J; Zhou Q; Liu Z; Cao L; Li L; Huang Y; Jiang K; Wang W; She F; Guan N; Hou Z; Li N; Wu L
JAMA Oncol; 2022 Aug; 8(8):1169-1176. PubMed ID: 35771546
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
[TBL] [Abstract][Full Text] [Related]
12. GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
Selle F; Heudel PE; Hardy-Bessard AC; Pozet A; Meunier J; Gladieff L; Lotz JP; Provansal M; Augereau P; Berton D; Bonichon-Lamichhane N; Orfeuvre H; Pautier P; Kalbacher E; Tazi Y; Spaeth D
Anticancer Res; 2020 Jul; 40(7):3939-3945. PubMed ID: 32620635
[TBL] [Abstract][Full Text] [Related]
13. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
15. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.
Motohashi T; Yabuno A; Michimae H; Ohishi T; Nonaka M; Takano M; Nishio S; Fujiwara H; Fujiwara K; Kondo E; Sugiyama T; Tabata T
J Gynecol Oncol; 2021 Jan; 32(1):e9. PubMed ID: 33185050
[TBL] [Abstract][Full Text] [Related]
17. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
Marth C; Vergote I; Scambia G; Oberaigner W; Clamp A; Berger R; Kurzeder C; Colombo N; Vuylsteke P; Lorusso D; Hall M; Renard V; Pignata S; Kristeleit R; Altintas S; Rustin G; Wenham RM; Mirza MR; Fong PC; Oza A; Monk BJ; Ma H; Vogl FD; Bach BA
Eur J Cancer; 2017 Jan; 70():111-121. PubMed ID: 27914241
[TBL] [Abstract][Full Text] [Related]
18. Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
Yamada Y; Kawaguchi R; Ito F; Iwai K; Niiro E; Shigetomi H; Tanase Y; Kobayashi H
J Obstet Gynaecol Res; 2017 Jul; 43(7):1194-1199. PubMed ID: 28544386
[TBL] [Abstract][Full Text] [Related]
19. Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience.
Dear RF; Gao B; Harnett P
Asia Pac J Clin Oncol; 2010 Mar; 6(1):66-73. PubMed ID: 20398040
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
